Table 2.
Chemotherapy regimen applied during each cycle.
| Patient number | Initial chemotherapy | Cycle 1 (Dose) | Cycle 2 (Dose) | Cycle 3 (Dose) | Cycle 4 (Dose) | Cycle 5 (Dose) |
|---|---|---|---|---|---|---|
| 1 | Mayo Clinic | UFT (60%) | UFT (80%) | UFT (100%) | UFT (90%) | UFT (90%) |
| 2 | FOLFOX6 | UFT (75%) | UFT (75%) | Raltitrexed (85%) | Raltitrexed (85%) | |
| 3 | Mayo Clinic | UFT (90%) | UFT ( 90%) | UFT (90%) | UFT (90%) | UFT (90%) |
| 4 | Mayo Clinic | UFT (90%) | UFT (90%) | UFT (90%) | UFT (90%) | UFT (90%) |
| 5 | Mayo Clinic | UFT (90%) | UFT (90%) | UFT (90%) | UFT (90%) | UFT (90%) |
Mayo Clinic, 5-fluorouracil [5-FU] (425 mg/m2) + leucovorin (20 mg/m2) IV bolus day1 and 5; FOLFOX6, oxaliplatin (85 mg/m2) + leucovorin (200 mg/m2) + 5-FU bolus (400 mg/m2) + 5-FU infusion for 46 hours (2400 mg/m2); UFT, tegafur (300 mg/m2/day) in three doses + leucovorin 30 mg VO every 8 hours for 21 days every 28 days; raltitrexed, 3 mg/m2.